SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015053
Filing Date
2021-11-08
Accepted
2021-11-08 16:30:52
Documents
44
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20210930x10q.htm   iXBRL 10-Q 864986
2 EX-31.1 apre-20210930xex31d1.htm EX-31.1 9745
3 EX-31.2 apre-20210930xex31d2.htm EX-31.2 10545
4 EX-32.1 apre-20210930xex32d1.htm EX-32.1 6732
5 EX-32.2 apre-20210930xex32d2.htm EX-32.2 6725
  Complete submission text file 0001558370-21-015053.txt   2884391

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20210930.xsd EX-101.SCH 21014
7 EX-101.CAL apre-20210930_cal.xml EX-101.CAL 29545
8 EX-101.DEF apre-20210930_def.xml EX-101.DEF 46643
9 EX-101.LAB apre-20210930_lab.xml EX-101.LAB 199179
10 EX-101.PRE apre-20210930_pre.xml EX-101.PRE 130083
11 EXTRACTED XBRL INSTANCE DOCUMENT apre-20210930x10q_htm.xml XML 328566
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 211388417
SIC: 2834 Pharmaceutical Preparations